Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks

Cancer-epigenetics comes of age

1999 • 2,379 citations

Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating Agents

2000 • 2,127 citations

Aberrant CpG-island methylation has non-random and tumour-type–specific patterns

2000 • 1,344 citations

MeCP2 Is a Transcriptional Repressor with Abundant Binding Sites in Genomic Chromatin

1997 • 1,258 citations

Estimation of Small Percentages of Fœtal Hæmoglobin

1959 • 1,047 citations

Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells

1988 • 891 citations

The DNA methylation paradox

1999 • 642 citations

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

2000 • 460 citations

5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.

1982 • 396 citations

Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides

1987 • 356 citations

Modified deoxyoligonucleotides stable to exonuclease degradation in serum

1991 • 356 citations

DNA (cytosine-5)-methyltransferases in mouse cells and tissues. studies with a mechanism-based probe

1997 • 353 citations

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

1999 • 350 citations

DNA methylation patterns Formation and function

1984 • 312 citations

5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia

1983 • 248 citations

Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies

1997 • 225 citations

p53 mutational spectra and the role of methylated CpG sequences

2000 • 164 citations

Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.

1999 • 152 citations

A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.

2000 • 128 citations

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys

1997 • 119 citations

DNA methylation properties: consequences for pharmacology

1994 • 105 citations

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.

1997 • 91 citations

Antisense oligonucleotides as therapeutics for malignant diseases.

1997 • 91 citations

Mouse DNA methylase: Methylation of native DNA

1979 • 86 citations

The DNA methylation machinery as a target for anticancer therapy

1996 • 84 citations

Oncogenic mechanisms mediated by DNA methylation

1997 • 78 citations

c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).

1999 • 77 citations

Gene Methylation Patterns and Expression

1984 • 71 citations

Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using direct injection fast anion-exchange chromatography and capillary gel electrophoresis

1994 • 70 citations

Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.

1996 • 53 citations

DNA methylation and globin gene expression in patients treated with 5-azacytidine.

1983 • 29 citations

Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma.

1987 • 20 citations

Antisense therapy for cancer.

1998 • 19 citations

Determination of cellular internalization of fluoresceinated oligonucleotides

2000 • 8 citations